Literature DB >> 23082884

Multiple resections for patients with glioblastoma: prolonging survival.

Kaisorn L Chaichana1, Patricia Zadnik, Jon D Weingart, Alessandro Olivi, Gary L Gallia, Jaishri Blakeley, Michael Lim, Henry Brem, Alfredo Quiñones-Hinojosa.   

Abstract

OBJECT: Glioblastoma is the most common and aggressive type of primary brain tumor in adults. These tumors recur regardless of intervention. This propensity to recur despite aggressive therapies has made many perceive that repeated resections have little utility. The goal of this study was to evaluate if patients who underwent repeat resections experienced improved survival as compared with patients with fewer numbers of resections, and whether the number of resections was an independent predictor of prolonged survival.
METHODS: The records of adult patients who underwent surgery for an intracranial primary glioblastoma at an academic tertiary-care institution between 1997 and 2007 were retrospectively reviewed. Multivariate proportionalhazards regression analysis was used to identify an association between glioblastoma resection number and survival after controlling for factors known to be associated with survival, such as age, functional status, periventricular location, extent of resection, and adjuvant therapy. Survival as a function of time was plotted using the Kaplan-Meier method, and survival rates were compared using log-rank analysis.
RESULTS: Five hundred seventy-eight patients with primary glioblastoma met the inclusion/exclusion criteria. At last follow-up, 354, 168, 41, and 15 patients underwent 1, 2, 3, or 4 resections, respectively. The median survival for patients who underwent 1, 2, 3, and 4 resections was 6.8, 15.5, 22.4, and 26.6 months (p < 0.05), respectively. In multivariate analysis, patients who underwent only 1 resection experienced shortened survival (relative risk [RR] 3.400, 95% CI 2.423-4.774; p < 0.0001) as compared with patients who underwent 2 (RR 0.688, 95% CI 0.525-0.898; p = 0.0006), 3 (RR 0.614, 95% CI 0.388-0.929; p = 0.02), or 4 (RR 0.600, 95% CI 0.238-0.853; p = 0.01) resections. These results were verified in a case-control evaluation, controlling for age, neurological function, periventricular tumor location, extent of resection, and adjuvant therapy. Patients who underwent 1, 2, or 3 resections had a median survival of 4.5, 16.2, and 24.4 months, respectively (p < 0.05). Additionally, the risk of infections or iatrogenic deficits did not increase with repeated resections in this patient population (p > 0.05).
CONCLUSIONS: Patients with glioblastoma will inevitably experience tumor recurrence. The present study shows that patients with recurrent glioblastoma can have improved survival with repeated resections. The findings of this study, however, may be limited by an intrinsic bias associated with patient selection. The authors attempted to minimize these biases by using strict inclusion criteria, multivariate analyses, and case-control evaluation.

Entities:  

Mesh:

Year:  2012        PMID: 23082884      PMCID: PMC3700339          DOI: 10.3171/2012.9.JNS1277

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  36 in total

1.  Reoperation for recurrent glioblastoma and anaplastic astrocytoma.

Authors:  G R Harsh; V A Levin; P H Gutin; M Seager; P Silver; C B Wilson
Journal:  Neurosurgery       Date:  1987-11       Impact factor: 4.654

Review 2.  New treatment strategies for malignant gliomas.

Authors:  Sith Sathornsumetee; Jeremy N Rich
Journal:  Expert Rev Anticancer Ther       Date:  2006-07       Impact factor: 4.512

3.  Glioblastoma multiforme-report of 267 cases treated at a single institution.

Authors:  Andreas M Stark; Arya Nabavi; Hubertus Maximilian Mehdorn; Ulrike Blömer
Journal:  Surg Neurol       Date:  2005-02

Review 4.  Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.

Authors:  Gary L Gallia; Steven Brem; Henry Brem
Journal:  J Natl Compr Canc Netw       Date:  2005-09       Impact factor: 11.908

5.  Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.

Authors:  B R Subach; T F Witham; D Kondziolka; L D Lunsford; M Bozik; D Schiff
Journal:  Neurosurgery       Date:  1999-07       Impact factor: 4.654

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 8.  The human subventricular zone: a source of new cells and a potential source of brain tumors.

Authors:  Alfredo Quiñones-Hinojosa; Kaisorn Chaichana
Journal:  Exp Neurol       Date:  2007-03-23       Impact factor: 5.330

9.  Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.

Authors:  M Westphal; Z Ram; V Riddle; D Hilt; E Bortey
Journal:  Acta Neurochir (Wien)       Date:  2006-02-17       Impact factor: 2.216

10.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.

Authors:  H Brem; S Piantadosi; P C Burger; M Walker; R Selker; N A Vick; K Black; M Sisti; S Brem; G Mohr
Journal:  Lancet       Date:  1995-04-22       Impact factor: 79.321

View more
  61 in total

1.  Minimally invasive resection of intracranial lesions using tubular retractors: a large, multi-surgeon, multi-institutional series.

Authors:  Daniel G Eichberg; Long Di; Ashish H Shah; Evan M Luther; Christina Jackson; Lina Marenco-Hillembrand; Kaisorn L Chaichana; Michael E Ivan; Robert M Starke; Ricardo J Komotar
Journal:  J Neurooncol       Date:  2020-06-18       Impact factor: 4.130

2.  The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis.

Authors:  Debra A Goldman; Koos Hovinga; Anne S Reiner; Yoshua Esquenazi; Viviane Tabar; Katherine S Panageas
Journal:  J Neurosurg       Date:  2018-11-01       Impact factor: 5.115

3.  Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis.

Authors:  Paolo Perrini; Carlo Gambacciani; Alessandro Weiss; Francesco Pasqualetti; Durim Delishaj; Fabiola Paiar; Riccardo Morganti; Riccardo Vannozzi; Lodovico Lutzemberger
Journal:  J Neurooncol       Date:  2016-11-14       Impact factor: 4.130

4.  Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.

Authors:  Michael Back; Cecelia E Gzell; Marina Kastelan; Linxin Guo; Helen R Wheeler
Journal:  Neurooncol Pract       Date:  2014-12-15

5.  Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival.

Authors:  Antonella Mangraviti; Stephany Y Tzeng; David Gullotti; Kristen L Kozielski; Jennifer E Kim; Michael Seng; Sara Abbadi; Paula Schiapparelli; Rachel Sarabia-Estrada; Angelo Vescovi; Henry Brem; Alessandro Olivi; Betty Tyler; Jordan J Green; Alfredo Quinones-Hinojosa
Journal:  Biomaterials       Date:  2016-05-21       Impact factor: 12.479

6.  Benefit of tumor resection for recurrent glioblastoma.

Authors:  Johanna Quick; Florian Gessler; Stephan Dützmann; Elke Hattingen; Patrick N Harter; Lutz M Weise; Kea Franz; Volker Seifert; Christian Senft
Journal:  J Neurooncol       Date:  2014-02-15       Impact factor: 4.130

Review 7.  Non-viral nucleic acid containing nanoparticles as cancer therapeutics.

Authors:  Kristen L Kozielski; Yuan Rui; Jordan J Green
Journal:  Expert Opin Drug Deliv       Date:  2016-06-06       Impact factor: 6.648

Review 8.  Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.

Authors:  Kaisorn L Chaichana; Leon Pinheiro; Henry Brem
Journal:  Ther Deliv       Date:  2015-03

9.  Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

Authors:  Alysson Wann; Patrick A Tully; Elizabeth H Barnes; Zarnie Lwin; Rosalind Jeffree; Katharine J Drummond; Hui Gan; Mustafa Khasraw
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

10.  Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.

Authors:  Federico Pessina; Pierina Navarria; Luca Cozzi; Stefano Tomatis; Marco Riva; Anna Maria Ascolese; Armando Santoro; Matteo Simonelli; Lorenzo Bello; Marta Scorsetti
Journal:  J Neurooncol       Date:  2016-11-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.